NCT00144300 is a Phase 4 clinical trial of Mirapex in Parkinson Disease, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT00144300?

NCT00144300 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT00144300?

Interventions in NCT00144300: Mirapex, Requip.

What condition does NCT00144300 study?

NCT00144300 studies Parkinson Disease.

Is NCT00144300 still recruiting?

NCT00144300 is currently completed. Last updated 17 February 2014.

Are results published for NCT00144300?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-02-17 · How we verify

NCT00144300

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients

Completed Phase 4 Results posted Last updated 17 February 2014

What this trial tests

Phase 4 trial testing Mirapex in Parkinson Disease in 246 participants. Completed.

Timeline

1 January 2005

Primary endpoint
1 September 2010

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	246
Start date	1 January 2005
Primary completion	1 September 2010
Sites	21 locations across United States

Drugs / interventions tested

Mirapex — full drug profile →
Requip — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

30 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Expert Panel Overall Assessment Following 2 Years on Drug
Time frame: up to 2 years
Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments

Sponsor's own description

To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Normando EM, Davis BM, De Groef L, Nizari S, et al · · 2016 · cited 75× · PMID 27535749 · DOI 10.1186/s40478-016-0346-z
Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease.
Seiple W, Jennings D, Rosen RB, Borchert L, et al · · 2016 · cited 3× · PMID 28078162 · DOI 10.1155/2016/8298503

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00144300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 17 February 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00144300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing